Cancers, Vol. 13, Pages 3801: Functional Analysis of Non-Genetic Resistance to Platinum in Epithelial Ovarian Cancer Reveals a Role for the MBD3-NuRD Complex in Resistance Development
Cancers, Vol. 13, Pages 3801: Functional Analysis of Non-Genetic Resistance to Platinum in Epithelial Ovarian Cancer Reveals a Role for the MBD3-NuRD Complex in Resistance Development
Cancers doi: 10.3390/cancers13153801
Authors:
Tabea L. Bauer
Katrin Collmar
Till Kaltofen
Ann-Katrin Loeffler
Lorena Decker
Jan Mueller
Sabine Pinter
Stephan A. Eisler
Sven Mahner
Patricia Fraungruber
Stefan Kommoss
Annette Staebler
Lewis Francis
R. Steven Conlan
Johannes Zuber
Udo Jeschke
Fabian Trillsch
Philipp Rathert
Epithelial ovarian cancer (EOC) is the most lethal disease of the female reproductive tract, and although most patients respond to the initial treatment with platinum (cPt)-based compounds, relapse is very common. We investigated the role of epigenetic changes in cPt-sensitive and -resistant EOC cell lines and found distinct differences in their enhancer landscape. Clinical data revealed that two genes (JAK1 and FGF10), which gained large enhancer clusters in resistant EOC cell lines, could provide novel biomarkers for early patient stratification with statistical independence for JAK1. To modulate the enhancer remodeling process and prevent the acquisition of cPt resistance in EOC cells, we performed a chromatin-focused RNAi screen in the presence of cPt. We identified subunits of the Nucleosome Remodeling and Deacetylase (NuRD) complex as critical factors sensitizing the EOC cell line A2780 to platinum treatment. Suppression of the Met...
Source: Cancers - Category: Cancer & Oncology Authors: Tabea L. Bauer Katrin Collmar Till Kaltofen Ann-Katrin Loeffler Lorena Decker Jan Mueller Sabine Pinter Stephan A. Eisler Sven Mahner Patricia Fraungruber Stefan Kommoss Annette Staebler Lewis Francis R. Steven Conlan Johannes Zuber Udo Jeschke Fabian Tri Tags: Article Source Type: research
More News: Cancer | Cancer & Oncology | Epithelial Cancer | Genetics | Mergers and Aquisitions | Ovarian Cancer | Ovaries | Statistics